BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 26, 2016
View Archived Issues
Cancer Research Technology announces ENPP2 inhibitors
Read More
Rugen Holdings reports NR2B receptor antagonists
Read More
USPI reports successful completion of preclinical testing of PROACT-D
Read More
Galectin's GR-MD-02 doesn't perform well enough in phase IIa trial
Read More
Mitsubishi Tanabe files application in Japan for combination drug for type 2 diabetes mellitus
Read More
Lundbeck updates progress of second quarter 2016
Read More
Novartis presents novel series of small molecule CSN5 inhibitors for the treatment of cancer
Read More
Suven describes novel series of amides as 5-HT4 receptor agonists for the treatment of AD
Read More
Immunovaccine releases new data from phase I/Ib study of DPX-Survivac in ovarian cancer
Read More
Sorrento Therapeutics discloses anti-HER2 antibody-anthracycline conjugates
Read More
FDA clears IND for phase I trial of DeuteRx's DRX-065
Read More
Immunophotonics doses first patient in trial of inCVAX
Read More
U.S. government contract supports Chembio Diagnostics' development of Zika point-of-care tests
Read More
Janssen describes novel tau protein PET imaging ligand [18F]JNJ-311 at ACS
Read More
BioLineRx enters joint venture with I-Bridge Capital
Read More
Factor IXa inhibitor CFM-184 shows anticoagulant potential
Read More
Positive results for Armetheon's phase I trial of tecarfarin
Read More
Lee's Pharmaceutical and Beijing Shenogen Pharma collaborate on combination product in China
Read More
Neuroderm starts enrollment in phase III trial of ND-0612L
Read More
FDA grants fast track status to Mallinckrodt's Synacthen Depot
Read More
Researchers from Genentech identify novel potent and selective NIK inhibitors
Read More
EXPAND phase III study meets its primary endpoint
Read More
Biotie Therapies' BTT-1023 receives FDA orphan drug designation
Read More
FDA grants orphan drug designation to TG Therapeutics' ublituximab
Read More